Kornimate/medical-research-clean huggingface dataset:
tympanic thermometer study

Conditions: Body Temperature Changes; Fever

Summary: the goal of this study is to collect febrile, healthy, and in some instances cold temperature data from human subjects ranging from newborns to geriatrics. this data will be used to develop a new thermometer.


Eligibility criteria:
inclusion criteria: * age: normal weight (≥2.5kg), full-term (37 weeks gestation) newborn to geriatric adult. * participant, legal guardian, or healthcare proxy is able to give consent to participate. * participant, legal guardian, or healthcare proxy speaks fluent english. exclusion criteria: * the subject does not meet the inclusion criteria. * the subject has anatomical abnormalities that would affect temperature. * the subject has blood or drainage in the external ear canal. * the subject has had something in their ear for a prolonged period, such as a hearing aid or headphones. the subject may be included if the hearing aid or headphones are removed at least 30 minutes prior to taking ear temperature. * the subject has been lying on ear within 30 minutes of data collection. the subject may be included if they wait 30 minutes prior to having an ear temperature measurement taken. * the subject exhibits symptoms of an acute or chronic inflammatory condition of the external ear canal. an example would be swimmer's ear. the subject may be included if the acute or chronic inflammatory condition is isolated to one ear, then the other ear may be used for data collection. * the subject has an ear obstruction or excess cerumen build-up. * the subject is in acute distress, i.e., severe pain, severe emotional distress or agitation that would inhibit them from participating in a tympanic ear temperature study. * the subject has any known contraindication to oral, ear, or axillary temperature measurements. * the subject has used ear drops in the last 8 hours. the subject may be included if the other ear was not medicated with ear drops in the last 8 hours. * the subject (age 5+) has consumed food or drink, or smoked, within the last 20 minutes. the subject may be included if they wait 20 minutes prior to taking oral temperature. * the subject has taken an antipyretic (ex: tylenol, motrin, aspirin) in the last 120 minutes.
decongestion guided by vexus score or lung ultrasound for renal recovery in patients with cardiorenal syndrome type -1

Conditions: Cardiorenal Syndrome Type 1

Summary: the goal of this observational study is to evaluate the role of vexus score and lung ultrasound to guide decongestive therapy in patients with cardiorenal syndrome type -1. the main question it aims to answer is: can the vexus score and lung ultrasound guide the efffect of decongestive therapy on kfr and decongestion metrics in patients with crs-1 compared to standard assesment ?


Eligibility criteria:
inclusion criteria: * • patients of both genders aged 18-65 years old. * patients with crs1 criteria (worsening of renal function due to acute heart failure manifested by : ( dyspnea , orthopnea ,hypoxia , congested neck veins , oliguria and congestion in imaging.) * patients with modified lung ultrasound score(luss) more than 15. exclusion criteria: * • refusal to participate. * patients with renal transplantation. * unknowing baseline creatinine. * patients with a life-threatening indication of rrt (defined as intractable hyperkalemia, acidosis, uremic symptoms) at enrollment, * rrt before recruitment, * known prehospitalization advanced chronic kidney disease (defined by an estimated gfr \<30 ml/min/1.73 m2 or chronic rrt), * use of extracorporeal membrane oxygenation (ecmo), * diagnosis of hepatic cirrhosis or other condition with portal hypertension * or postrenal causes of aki
transcranial electrical stimulation in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: first the investigators will examine if the blood flow in the brain is different in patients with multiple sclerosis compared to healthy volunteers. how? - the blood flow of the subjects is imaged by use of a special mri-technique. secondly, the investigators will examine if the blood flow can determine disease progression. how? - multiple sclerosis patients are asked for a follow-up visit after two years. the main goal is to understand the effect of transcranial direct current stimulation (tdcs) on the cerebral blood flow. * does tdcs result in a different blood flow, in which brain regions? * is there a difference between healthy volunteers and multiple sclerosis patients? how? - participants get two session of tdcs. before, during and after stimulation mri scans are performed.

comparison of cbf between healthy volunteers and ms patients: - arterial spin labelling (asl) is used to investigate cerebral blood flow in patients with ms and healthy volunteers. the effect of transcranial direct current stimulation (tdcs) on cerebral blood flow: * asl scans are performed before-, during-, and after tdcs * each subject will receive active and sham tdcs (seperated by at least two days) (cross-over design). follow-up visit: * after two years, patients with ms are re-invited. * this visit will include a new neuropsychological evaluation, blood sampling and additional brain scans.

Eligibility criteria:
inclusion criteria - ms patient * edss ≥ 2 and edss ≤ 6.5 * age ≥ 18 exclusion criteria - ms patient * edss \> 6.5 * incompatibility with mri * relapse within three months before the study and its use of corticosteroids * disabling concomitant neuropsychiatric diseases * chance of pregnancy, breastfeeding * contraindications to tdcs inclusion criteria - healthy volunteer • age ≥ 18 exclusion criteria - healthy volunteer * incompatibility with mri * disabling concomitant neuropsychiatric diseases * chance of pregnancy, breastfeeding * contraindications to tdcs

Keywords: multiple sclerosis cerebral hemodynamics cerebral circulation cerebral hypoperfusion transcranial direct current stimulation electrical stimulation
study of two techniques of rectal reservoir in low anterior resection of rectum

Conditions: Low Rectal Adenocarcinoma

Summary: the aim of the study cgd-01/2000 was to investigate wheter a transverse coloplasty pouch is able to improve functional results and quality of life after coloanal anastomosis.


Eligibility criteria:
inclusion criteria: * low or middle rectal adenocarcinoma without involvement of the anal sphincter * neoadjuvant chemoradiotherapy * age older than 18 years * wexner index of less than 5 * signed informed consent exclusion criteria: * involvement of the anal sphincter * wexner index of 5 or more * declined informed consent * psychological or social problems

Keywords: low rectal adenocarcinoma
a study of orelabrutinib in patients with itp

Conditions: Immune Thrombocytopenia

Summary: this project was undertaken to evaluate the efficacy and safety of btk inhibitor orelabrutinib for the secondary treatment of adults with primary immune thrombocytopenia (itp).

the investigators are undertaking a prospective trial of 10 adults with itp in china. orelabrutinib is administered as 50 mg po. qd for 6 weeks. platelet count, bleeding and other symptoms were evaluated before and after treatment. adverse events are also recorded throughout the study.

Eligibility criteria:
inclusion criteria: * confirmed primary refractory itp * platelet counts \<30×10\^9/l or with bleeding symptoms * willing and able to sign written informed consent exclusion criteria: * secondary thrombocytopenia * received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 6 months before the screening visit * hiv infection or hepatitis b virus or hepatitis c virus infections * malignancy * severe medical condition (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia) * nursing or pregnant patients * patients who are deemed unsuitable for the study by the investigator

Keywords: bruton's tyrosine kinase
ctdna as a novel biomarker of treatment efficacy in patients with ovarian cancer

Conditions: High-grade Serous Ovarian Cancer; Circulating Tumor DNA

Summary: this study is a prospective observational clinical trial. patients who were diagnosed and treated for the first time were enrolled and their surgical pathology was confirmed to be high-grade serous ovarian cancer. at the same time, these patients will receive first-line maintenance treatment with parp inhibitors after traditional chemotherapy. during the trial period, patients' plasma will be collected before surgery, after chemotherapy, during targeted maintenance therapy, and during disease progression, and ctdna-specific genomes will be detected, and clinical data will be collected over the same period. it is expected that specific ctdna can be used to predict the efficacy of parp inhibitors in patients with ovarian cancer, and to detect the recurrence of the disease early.


Eligibility criteria:
inclusion criteria: 1. ovarian cancer first diagnosed and treated; 2. pathologically confirmed as epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer; 3. the stage of the disease is ii-iv, and surgery will be performed after evaluation; 4. age ≥ 18 years old; 5. subjects and their families fully understand the research plan and sign an informed consent form. exclusion criteria: 1. pathologically confirmed as non-epithelial ovarian cancer; 2. surgical treatment cannot be performed after evaluation; 3. malignant tumors found in other parts of the study were found within five years before enrollment or at the time of enrollment; 4. patients who do not agree to use clinical first-line targeted drugs; 5. severe mental illness; 6. severe cardiovascular disease, uncontrollable infection, or other uncontrollable comorbid diseases.
comparison of the vocal cord imaging techniques after thyroidectomy

Conditions: Thyroid Nodule

Summary: recurrent nerve palsy is a complication of thyroidectomy. most surgeons want to visualize the vocal cords after tyroidectomy. the aim is to compare the direct laringoscopy, videolaringoscopy, fiberoptic laringoscopy and ultrasonography methods in terms of efficacy, duration and hemodynamic responses during the procedure.

the vocal cord will be visualised after the extubation with one of the following methods: direct laringoscopy videolaringoscopy fiberoptic laringoscopy ultrasonography the of efficacy of the method (0= not able to visualize the vocal cords, 1= the vocal cords were visualized) duration of the procedure and hemodynamic responses (heart rate, mean arterial pressure) during the procedure will be compared between the groups.

Eligibility criteria:
inclusion criteria: * benign or malignant thyroid pathology exclusion criteria: * anticipated difficult intubation
an evaluation of the fitting success rate of senofilcon a soft contact lenses in three designs.

Conditions: Myopia

Summary: this study will compare the on-eye fitting characteristics of three types of contact lenses. each lens pair will be worn for 30 to 45 minutes before assessment and the results will be compared to mathematically calculated fitting characteristics.

this will be an approx. 40-60 subject, one-day, double-masked, randomised, repeated measures study. each subject will wear the three lens types bilaterally in random succession, a total of six lenses will therefore be worn by each subject (3 per eye).

Eligibility criteria:
inclusion criteria: * age 18-70 years. * able to read, comprehend and sign an informed consent. * willing to comply with the wear and study assessment schedule. * spherical distance prescription between -0.50 and -6.00 (inc.). * astigmatism, if present,≤1.50dc in both eyes. * have normal eyes with no evidence of any ocular abnormality or disease. for the purposes of this study a normal eye is defined as one having: a clear central cornea. no anterior segment disorders. no clinically significant slit lamp findings (i.e. corneal oedema, significant staining, central scarring, infiltrates, active neovascularisation). no other active ocular disease (including pterygia). exclusion criteria: * previous anterior ocular surgery * any active corneal infection, injury or inflammation . •large pinguecula likely to affect soft lens fit * systemic or ocular disease or medication which might interfere with cl wear * pregnancy or breastfeeding * participation in any concurrent trial

Keywords: contact lens the young theory
genetic and immunity in heart failure

Conditions: Heart Failure

Summary: heart failure is a major health problem with serious consequences on mortality and morbidity worldwide. in chronic heart failure an alteration of the inflammatory state occur. the aim of this study will be to describe the relationship between markers of inflammation in patients with heart failure with preserved ejection fraction, gender differences and advanced age. the study sample will include patients hospitalized in the unit of general medicine and aging with a diagnosis of heart failure based on the guidelines. clinical and demographic data will be collected from the electronic records of our hospital system. a complete history will be obtained, including the possible etiology of heart failure, cardiac and noncardiac comorbidities, all medications, intracardiac devices, and chronic oxygen treatment. all patients will be documented for peripheral edema, pulmonary rales and jugular vein distension. nyha (new york heart association) class will be identified at discharge. in addition, a blood sample will be taken to obtain a complete panel including total blood count, glycemia, renal function, electrolytes and liver function tests, as per standardized clinical practice. nt-probnp (amino-terminal pro natriuretic peptide b) will be measured at admission and discharge from the hospital, as per standardized clinical practice. echocardiograms will be performed by experienced operators of the echocardiography service of our polyclinic, according to the american society of echocardiography guidelines. a single additional blood sample will be collected during one of the normal routine blood draws for all immunological tests. plasma from each participant will be isolated to determine the concentrations of several cytokines. circulating lymphocytes will be separated according to ficoll gradient (peripheral blood mononuclear cells, pbmc) into the two different components of immunity (b and t lymphocytes) with different inflammatory phenotypes evaluation of enhancer (hs)1,2 polymorphisms and estrogen levels: dna purifications and amplifications will be performed from an aliquot of the single whole blood sample collected for the evaluation of the inflammatory profile. genomic dna will be isolated and 9 snps in four specific polymorphic regions of the 3'-1 regulatory region (3'rr-1) of the human immunoglobulin (igh) heavy chain locus will be sequenced. follow-up will be performed by telephone contacting the patients or their caregivers 90 days after discharge.


Eligibility criteria:
inclusion criteria: * adult patients (age ≥18 years) with exacerbation of chronic heart failure with reduced or preserved ejection fraction, * stable haemodynamic conditions, without the need for inotropic support at the time of admission to the ward, * signature of the informed consent. exclusion criteria: . age \<18 years; * pregnancy; * acute coronary syndromes; * end-stage renal failure (clearance \<30 ml/min) or dialysis; * ongoing sepsis; * bed rest syndrome; * any concomitant neoplasm, * congenital and acquired immunodeficiencies (hiv, immunosuppressive drugs).
a pharmacokinetics and safety study in subjects with renal impairment

Conditions: Renal Impairment

Summary: the purpose of this study is to assess the single dose pharmacokinetics (pk) and safety of tr701 fa in subjects with advance renal impairment.

to assess the pharmacokinetics (pk) and evaluate the safety of intravenous (iv) infusion of tr-701 free acid (fa) in subjects with advanced renal impairment compared with matched control subjects with normal renal function

Eligibility criteria:
inclusion criteria: * bmi between 18.0 and 40.0 kg/m2 inclusive * male or female subjects between 18 and 75 years of age * stable dosage of medication for 30 days * for dialysis patients, receiving chronic and stable maintenance hemodialysis for at least 3 months exclusion criteria: * functioning transplanted solid organ * high tyramine diet * significant, unstable, or life-threatening condition or organ or system condition or disease, other than kidney disease in renal subjects

Keywords: renal impairment
causative diagnosis on prosthetic joint infections: establishment of a comprehensive diagnostic strategy

Conditions: Prosthetic Joint Infections

Summary: on joint orthopaedic hardware infections are one of the most frequently encountered complications in orthopaedic surgery. however 6% of the cultures remain sterile, etiological diagnosis cannot be established despite obvious signs of infection. as part of this research project, we have developed a new strategy diagnosis including directly the use of pcr to reduce the number of negative results. this should have a major therapeutic impact in terms of timeliness and specificity of antibiotic. primary: evaluate the effectiveness of the new diagnostic strategy on etiological identification of prosthesis infections. hypothesis: minimum 6 percent increase in the number of patients with an etiological diagnosis of infection on prosthesis.


Eligibility criteria:
inclusion criteria: * patient is more than 18 years old. * patient with a prescription of a microbiologic diagnostic of prosthetic joint infection * patient who do not declined to have his medical records reviewed for research * patient with health insurance exclusion criteria: * patient minor (\<18 years). * pregnant or lactating woman. * major under guardianship patient. * patient deprived of liberty or under court order
a study to evaluate the efficacy and safety of three experimental drugs compared with telaprevir (a licensed product) for treatment of chronic hepatitis c infection in treatment-experienced adults

Conditions: Chronic Hepatitis C Infection

Summary: the purpose of this study is to evaluate the safety and antiviral activity of 3 direct-acting antiviral agents (daas; abt-450/ritonavir/abt-267 \[abt-450/r/abt-267; abt-267 also known as ombitasvir\] and abt-333 \[also known as dasabuvir\]) plus ribavirin (rbv) compared with telaprevir (tpv) with pegylated interferon/ribavirin (pegifn/rbv) in patients with chronic hepatitis c virus genotype 1 (hcv gt1) infection without cirrhosis who were previously treated with pegylated interferon/ribavirin (pegifn/rbv).

a randomized, open-label, parallel-arm, multicenter study to evaluate the safety and antiviral activity of the 3-daa regimen (abt-450/ritonavir/abt-267 \[abt-450/r/abt-267\] and abt-333) plus ribavirin (3-daa/rbv) compared with the combination of telaprevir (tpv) with rbv and pegifn (tpv/rbv) in noncirrhotic participants with chronic hepatitis c virus genotype 1 (hcv gt1) infection who were previously treated with pegylated interferon/ribavirin (pegifn/rbv). participants were randomized in a 2:1 ratio to receive 3-daa/rbv (abt-450/r/abt-267 and abt-333 plus rbv for 12 weeks) or tpv/rbv (tpv co-administered with pegifn and rbv for 12 weeks, followed by followed by pegifn and rbv for either 12 or 36 weeks, per local prescribing information).

Eligibility criteria:
inclusion criteria: * females must be practicing specific forms of birth control on study treatment, or be post-menopausal for more than 2 years or surgically sterile * chronic hepatitis c infection (positive for anti-hcv antibody or hcv rna at least 6 months before screening and at the time of screening; or positive for anti-hcv antibody or hcv rna at the time of screening with a liver biopsy consistent with chronic hcv infection) * screening laboratory result indicating hcv genotype 1 infection (hcv gt1) * participant must have documentation of adherence to a prior pegifn/rbv combination therapy and meet one of the protocol definitions for treatment failure: null responder, partial responder, relapser * no evidence of liver cirrhosis exclusion criteria: * positive hepatitis b surface antigen or anti-human immunodeficiency virus antibody * positive screen for drugs or alcohol * significant sensitivity to any drug * use of contraindicated medications within 2 weeks of dosing * abnormal laboratory tests

Keywords: partial responder interferon free treatment-experienced relapser hepatitis c virus null responder hepatitis c genotype 1 paritaprevir ombitasvir dasabuvir ribavirin viekira pak chronic hepatitis c
a comparison of stryker hybrid arch bars

Conditions: Fracture Mandible

Summary: patients who sustain a fracture of the lower jaw are typically treated by wiring the teeth together or using small titanium plates and screws to fix the fracture. with either technique the upper and lower teeth are held together to ensure that the fracture is held in the correct position during healing (for closed reduction) or while the plate and screws are applied (for open reduction). the teeth can be held together using erich arch bars which are a type of braces that are temporarily wired to the existing teeth. these stay in place for 6 weeks until the fracture has healed even though the patient is able to open his mouth immediately after the surgery is complete. the alternative to the traditional erich arch bars is a relatively new type of arch bar (stryker hybrid) that is screwed to the jaw bone rather than wired to the teeth. the purpose of this study is to compare the two types of arch bars in terms of the speed with which they can be applied as well as any difference in fracture healing


Eligibility criteria:
inclusion criteria: 1. mandible fracture involving subcondyle, ramus, angle, body, parasymphysis and symphysis 2. age 18 years - 90 years 3. ability to give informed consent 4. minimum 6 weeks follow-up 5. pre and post-operative panoramic xrays exclusion criteria: 1. comminuted fractures 2. infected fractures 3. previously treated fractures 4. complete edentulism 5. gun shot wounds 6. pregnancy or breast feeding
kanagawa combination anti-hypertensive therapy (k-cat)

Conditions: Hypertension

Summary: the purpose of this study is to compare the effect and safety of the antihypertensive combination therapies between losartan/amlodipine and fixed dose drug of losartan/hydrochlorothiazide.

the combination therapy with multiple antihypertensive drugs is recommended in the patients who are uncontrolled with monotherapy. diuretics increase the activities of renin-angiotensin-aldosterone system (ras), and angiotensin receptor blockers (arb) depress blood pressure potently in the state of increased ras activities. thus, the combination therapy with arb and diuretics is expected to lower the blood pressure synergistically. this combination therapy is also expected to reduce the side effects of each drug. in this study, we will compare the effect and safety of the combination therapies between losartan/amlodipine and fixed dose drug of losartan/hydrochlorothiazide.

Eligibility criteria:
inclusion criteria: * under treatment of hypertension with arb monotherapy for more than one month. * systolic blood pressure more than 140mmhg and less than 160mmhg or diastolic blood pressure more than 90mmhg and less than 100mmhg in sitting position. * in diabetic or ckd patients, systolic blood pressure more than 130mmhg and less than 160mmhg or diastolic blood pressure more than 80mmhg and less than 100mmhg in sitting position. exclusion criteria: * uncontrolled hypertension (diastolic blood pressure \>120mmhg) * uncontrolled diabetes mellitus (hba1c\>9.0%) * acute myocardial infarction, stroke and other cardiovascular events within six months * the history of gout, or uric acid\>8.0mg/dl * serum creatinine\>2.0mg/dl * sever liver dysfunction * bilateral renovascular stenosis * secondary hypertension * malignant hypertension * uncontrolled arrhythmia * pregnancy or possibility of pregnancy * hypersensitivity to trial drug

Keywords: hypertension angiotensin receptor blocker diuretic combination therapy